Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP. Lip GYH, et al. Among authors: nordaby m. Am Heart J. 2019 Jun;212:13-22. doi: 10.1016/j.ahj.2019.02.006. Epub 2019 Mar 1. Am Heart J. 2019. PMID: 30928824 Clinical Trial.
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).
Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Ten Berg JM, et al. Among authors: nordaby m. Am J Cardiol. 2020 Mar 1;125(5):735-743. doi: 10.1016/j.amjcard.2019.11.029. Epub 2019 Dec 9. Am J Cardiol. 2020. PMID: 31924322 Free article.
Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.
De Caterina R, Procopio A, Lopez Sendon JL, Raev D, Mehta SR, Opolski G, Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Kleine E, Ten Berg JM, Bhatt DL, Miede C, Nordaby M, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. De Caterina R, et al. Among authors: nordaby m. Am J Med. 2020 Nov;133(11):1302-1312. doi: 10.1016/j.amjmed.2020.03.045. Epub 2020 May 7. Am J Med. 2020. PMID: 32389658 Free article. Clinical Trial.
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials).
Eccleston DS, Kim JM, Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CP. Eccleston DS, et al. Among authors: nordaby m. Clin Cardiol. 2021 Jul;44(7):1002-1010. doi: 10.1002/clc.23649. Epub 2021 May 27. Clin Cardiol. 2021. PMID: 34042199 Free PMC article.
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Cannon CP, et al. Among authors: nordaby m. N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844193 Free article. Clinical Trial.
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP. Oldgren J, et al. Among authors: nordaby m. Eur Heart J. 2019 May 14;40(19):1553-1562. doi: 10.1093/eurheartj/ehz059. Eur Heart J. 2019. PMID: 30793734 Free PMC article. Clinical Trial.
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Hohnloser SH, et al. Among authors: nordaby m. JACC Cardiovasc Interv. 2019 Aug 26;12(16):1553-1561. doi: 10.1016/j.jcin.2019.05.050. JACC Cardiovasc Interv. 2019. PMID: 31439336 Free article. Clinical Trial.
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Ten Berg JM, et al. Among authors: nordaby m. JACC Cardiovasc Interv. 2019 Dec 9;12(23):2331-2341. doi: 10.1016/j.jcin.2019.08.039. JACC Cardiovasc Interv. 2019. PMID: 31806214 Free article. Clinical Trial.
35 results